… clinical analysis of cancer patients undergoing oxaliplatin-based … Adult cancer patients with
moderate or severe cancer pain (an … are of poor quality and inconclusive and limited by low …

… , which is the pharmacological target of platinum complexes [… response, oxaliplatin can
trigger signals on cancer cells that … A dose-escalating phase I study was completed in the UK for …

… , 5-fluorouracil, irinotecan and oxaliplatin) 11 . A randomized … is associated with poor prognosis
in cancers in general 110 . … models, one study demonstrated that broad pharmacological …

… Therapy using gemcitabine and platinum analogues (cisplatin or oxaliplatin) did not give …
in a case study, with increased quality of life and clinical response in a patient with a poor PS […

… Despite advances in several pharmacological approaches, … in the TME because of poor
lymphatic drainage, a phenomenon … A dose-escalating single IV toxicity study of Nanoxel ® -PM …

… of 40 breast cancer patients before and after 13–21 days of dose escalating metformin (from …
Artemisinin (malaria treatment) derivatives may be an alternative to oxaliplatin, as they are …

… and a phase Ib (dose escalating study) is ongoing in breast, colon, and prostate cancer patients
(… (NCT02413853, in combination with bevacizumab, leucovorin calcium, oxaliplatin, and …

… A dose-escalating phase I study of pazopanib was … because of severe liver impairment
in 5-10 % of patients [37, 38]. … the efficacy of Folfox regimen (oxaliplatin, folinic acid and 5-fluo…

… by rapid drug absorption of oxaliplatin into the tumor [118, 119]. … to successful treatment
of solid tumors include poor tumor … In a doseescalating study published in 1991, refractory …